- Home
- Publications
- Publication Search
- Publication Details
Title
Lower Grade Gliomas
Authors
Keywords
-
Journal
Current Neurology and Neuroscience Reports
Volume 20, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-22
DOI
10.1007/s11910-020-01040-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
- (2020) Fumi Higuchi et al. CLINICAL CANCER RESEARCH
- PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
- (2019) Shiv K. Gupta et al. Frontiers in Oncology
- Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
- (2019) Bin Fan et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
- (2019) Atsushi Natsume et al. JOURNAL OF CLINICAL ONCOLOGY
- Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.
- (2019) Martin J. Van Den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic correlates of disease progression and treatment response in prospectively characterized gliomas
- (2019) Philip Jonsson et al. CLINICAL CANCER RESEARCH
- CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
- (2019) Romain Appay et al. NEURO-ONCOLOGY
- Comprehensive Prognostic and Predictive Molecular Subgroup Analysis within the High-risk Treatment Arms of NRG Oncology/RTOG 9802: a Phase III Trial of RT versus RT + PCV in High-risk Low-grade Gliomas
- (2019) E.H. Bell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Longitudinal molecular trajectories of diffuse glioma in adults
- (2019) Floris P. Barthel et al. NATURE
- ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS
- (2019) Ingo Mellinghoff et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
- (2019) Quinn T Ostrom et al. NEURO-ONCOLOGY
- Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis
- (2018) Liang Xia et al. BMC CANCER
- Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis
- (2018) Chong Hyun Suh et al. EUROPEAN RADIOLOGY
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
- (2018) Samuel K. McBrayer et al. CELL
- A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
- (2018) Michael Platten et al. JOURNAL OF CLINICAL ONCOLOGY
- Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
- (2017) Gary Kohanbash et al. JOURNAL OF CLINICAL INVESTIGATION
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
- (2017) Ingo K Mellinghoff et al. NEURO-ONCOLOGY
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles
- (2017) Farshad Farshidfar et al. Cell Reports
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma
- (2016) Changho Choi et al. JOURNAL OF CLINICAL ONCOLOGY
- Maximizing safe resection of low- and high-grade glioma
- (2016) Shawn L. Hervey-Jumper et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
- (2016) Brigitta G Baumert et al. LANCET ONCOLOGY
- Mutations of myelodysplastic syndromes (MDS): An update
- (2016) Bani Bandana Ganguly et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
- (2016) Wolfgang Wick et al. NEURO-ONCOLOGY
- Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813
- (2016) Susan Chang et al. NEURO-ONCOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
- (2015) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
- (2015) Adriana Olar et al. ACTA NEUROPATHOLOGICA
- Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424
- (2015) Barbara J. Fisher et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas
- (2015) Gerald F. Reis et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
- (2015) Rutger K Balvers et al. Journal of Translational Medicine
- Insulator dysfunction and oncogene activation in IDH mutant gliomas
- (2015) William A. Flavahan et al. NATURE
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
- (2015) Pu Wang et al. Cell Reports
- The Value of Pre- and Intraoperative Adjuncts on the Extent of Resection of Hemispheric Low-Grade Gliomas: A Retrospective Analysis
- (2015) Olutayo Olubiyi et al. Journal of Neurological Surgery Part A-Central European Neurosurgery
- Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
- (2015) Serena Pellegatta et al. Acta Neuropathologica Communications
- International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
- (2014) David N. Louis et al. BRAIN PATHOLOGY
- Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
- (2014) S. K. Gupta et al. CLINICAL CANCER RESEARCH
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach
- (2014) H. Duffau et al. NEURO-ONCOLOGY
- IDH1 and IDH2 Mutations in Gliomas
- (2013) Adam L. Cohen et al. Current Neurology and Neuroscience Reports
- New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials
- (2013) T. Gorlia et al. NEURO-ONCOLOGY
- Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
- (2013) Johan Pallud et al. NEURO-ONCOLOGY
- TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
- (2013) P. J. Killela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Functional relevance of dynamic properties of Dimeric NADP-dependent Isocitrate Dehydrogenases
- (2012) Rithvik Vinekar et al. BMC BIOINFORMATICS
- Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
- (2012) Asgeir S. Jakola et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
- (2012) Sichen Li et al. NEURO-ONCOLOGY
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
- (2012) P Wang et al. ONCOGENE
- Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
- (2012) O. C. Andronesi et al. Science Translational Medicine
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
- (2011) A. B. Lassman et al. NEURO-ONCOLOGY
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
- (2011) Z. J. Reitman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
- (2011) C. Bettegowda et al. SCIENCE
- Molecular Classification of Low-Grade Diffuse Gliomas
- (2010) Young-Ho Kim et al. AMERICAN JOURNAL OF PATHOLOGY
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
- (2010) Michael Brada et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas
- (2009) Juan Martino et al. ACTA NEUROCHIRURGICA
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas
- (2008) Justin S. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More